ArticleThe Journal of clinical endocrinology and metabolism2025
Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II-Associated Non-Islet Cell Tumor Hypoglycemia.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Doege-Potter syndrome caused by a solitary fibrous tumor arising from the greater omentum: a case report.Clinical journal of gastroenterology · 2026Article
- Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II-Associated Non-Islet Cell Tumor Hypoglycemia.The Journal of clinical endocrinology and metabolism · 2025Article
- Case report: From metabolic instability to remission: a case of pheochromocytoma presenting as atypical diabetes.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
contextIn most cases of non-islet cell tumor hypoglycemia (NICTH), high molecular weight forms of insulin-like growth factor II, commonly referred to as big IGF-II, cause hypoglycemia. MicroRNA-483 (miR-483), encoded within an intron of IGF2, has been suggested to be coexpressed with IGF-II.
objectiveThe aim of this study is to demonstrate the utility and reliability of circulating miR-483 as a biomarker for diagnosis and therapeutic outcome of NICTH.
methodsSera from 145 cases of suspected NICTH, and postoperative sera from 25 surgical cases of confirmed NICTH were subjected to Western blot analysis and enzyme-linked immunosorbent assay for IGF-II and quantitative polymerase chain reaction analysis for miR-483-5p and -3p. Tissue miR-483 expression levels were compared between resected solitary fibrous tumors (SFTs) and their surrounding margins from 11 surgical cases.
resultsNICTH was confirmed in 100 out of 145 cases based on the detection of big IGF-II in their sera. Receiver operating characteristic curve analysis revealed that serum miR-483-5p had a better diagnostic ability for NICTH than serum IGF-II or the classical diagnostic marker the IGF-II to IGF-I ratio. Notably, serum miR-483-5p levels decreased significantly with the disappearance of big IGF-II after surgical tumor resection. Tissue miRNA-483-5p and -3p expression levels were significantly higher in resected SFT tissues than in their surgical margins.
conclusionCirculating miR-483-5p, derived from IGF-II-producing tumors, appears to be a more reliable biomarker for diagnosis and therapeutic outcome of NICTH than IGF-II or the IGF-II to IGF-I ratio. These findings highlight the clinical utility of miR-483-5p in the management of NICTH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.